Skip to content
CancerIndex

Publication

Clinical Outcomes of Pembrolizumab Combination Therapy in Heavily Pretreated PDTC and Anaplastic Thyroid Cancer.

Tim Brandenburg, Yara Maria Machlah, Lynn Marlene Srasra, Philipp Muchalla, Sarah Theurer, David Kersting, Manuel Maria Weber, Frank Weber, Henning Dralle, Harald Lahner, Dagmar Führer

European thyroid journalSep 28, 2026PMID 42804425doi:10.1530/ETJ-26-0053 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 30, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260930-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

BACKGROUND: Poorly differentiated (PDTC) and anaplastic thyroid carcinoma (ATC) are rare, aggressive malignancies with limited treatment options. Although targeted therapies for tumours harbouring BRAF V600E mutations or fusions involving NTRK1, NTRK2, NTRK3, or RET have expanded treatment options,…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.